Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC

Sara Moore; Bonnie Leung; Jonn Wu; Cheryl Ho

doi:10.1016/j.jtocrr.2020.100083

Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC

JTO Clin Res Rep. 2020 Aug 15;1(4):100083. doi: 10.1016/j.jtocrr.2020.100083. eCollection 2020 Nov.

Authors

Sara Moore^{1

2}, Bonnie Leung², Jonn Wu^{1

3}, Cheryl Ho^{1

2}

Affiliations

¹ Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
³ Department of Radiation Oncology, BC Cancer, Vancouver, British Columbia, Canada.

Abstract

Introduction: The treatment of locally recurrent NSCLC after initial curative therapy is variable. We sought to perform a real-world analysis of curative and palliative therapeutic strategies used in locally recurrent NSCLC and explore the impact of baseline factors and the previous and recurrent treatment on outcomes.

Methods: A retrospective cohort study was done including all patients with stage I to III NSCLC who were referred to BC Cancer and received curative-intent therapy between 2005 and 2012. Patients were followed up to determine whether they developed locoregional recurrence. Two cohorts were created: curative-intent treatment at recurrence (surgery, radiotherapy with ≥50Gy ± chemotherapy, stereotactic radiosurgery) and palliative treatment. The primary outcome was overall survival (OS).

Results: A total of 1571 patients received curative-intent therapy during the study period. Of these, 179 (11%) developed a local and regional recurrence. A total of 51 patients (28%) were treated with curative intent at recurrence (12 surgery, 39 radiotherapy ± chemotherapy), and 128 (72%) received palliative treatment only. Patients receiving curative-intent therapy were more likely to have an Eastern Cooperative Oncology Group performance status of 0 to 1 (90% versus 58%), earlier stage at diagnosis (51% stage I) and receive more aggressive staging investigations at recurrence, pathologic confirmation (75% versus 27%) and positron emission tomography (77% versus 27%). OS was longer in the cohort receiving curative-intent therapy, with an OS of 34.3 months versus 9.8 months (p < 0.001) in palliative treatment.

Conclusions: In this real-world population, isolated locoregional recurrences occurred in 11% of patients. Curative-intent treatment at recurrence is associated with a reasonable chance of long-term survival, making aggressive therapy of locoregional recurrences an important treatment consideration.

Keywords: Curative-intent; Radiotherapy; Real-world evidence; Recurrence; Salvage; Surgery.